PRESIDENT HAS SERVED AS A REVIEWER FOR THE FELLOWSHIP: CELL BIOLOGY, DEVELOPMENTAL BIOLOGY, AND BIOENGINEERING [F05] STUDY SECTION FOR THE NIH
PDX Pharma’s President has served as a reviewer for the Fellowship: Cell Biology, Developmental Biology, and Bioengineering [F05] Study Section for the National Institute of Health (NIH) held on February 28, 2017 – March 1, 2017.
pdx news
PDX pharma awarded SBIR grant from the National Cancer Institute (total of $2.4M) for the development of PETTRA, a novel lung cancer treatment
PDX Pharma awarded two-year $1.87M phase II SBIR grant from the National Cancer Institute (NCI) for the development of ARAC-02, a novel lung cancer treatment